Market Place
Sourcing Support
Akeso Enrolls 1st Patient in Ivonescimab Biliary Tract Cancer Trial
31 Oct 2024 //
PR NEWSWIRE
Govt asks manufacturers to cut price of 3 anti-cancer drugs
29 Oct 2024 //
ECONOMICTIMES
AstraZeneca Pharma India to launch Tremelimumab
23 Sep 2024 //
INDIANPHARMAPOST
AIM ImmunoTech Reports Positive Data In Pancreatic Cancer Study
19 Sep 2024 //
GLOBENEWSWIRE
AstraZeneca`s Imfinzi extends life in bladder cancer type
17 Sep 2024 //
FIERCE PHARMA
Imfinzi Plus Imjudo Shows 5-Year Survival In Liver Cancer
16 Sep 2024 //
BUSINESSWIRE
IMFINZI Reduces Recurrence Risk In Bladder Cancer In NIAGARA Trial
15 Sep 2024 //
BUSINESSWIRE
Alchemab appoints Co-Founder Jane Osbourn as Chief Executive Officer
12 Sep 2024 //
PR NEWSWIRE
AstraZeneca Advances Cancer Care Standards at WCLC and ESMO 2024
03 Sep 2024 //
BUSINESSWIRE
Imfinzi Approved In U.S. For Resectable Non-Small Cell Lung Cancer
16 Aug 2024 //
BUSINESSWIRE
AstraZeneca`s Imfinzi gets FDA priority review for type of lung cancer
15 Aug 2024 //
REUTERS
Argenx`s Vyvgart Competes Well With AstraZeneca In Myasthenia Gravis
25 Jul 2024 //
FIERCE PHARMA
AstraZeneca`s Biologic Imfinzi (Durvalumab) Receives Suppl Approvals in US
24 Jul 2024 //
FDA
FDA Flags Potential ‘Overtreatment’ for NSCLC With AstraZeneca’s Imfinzi
24 Jul 2024 //
BIOSPACE
AZ`s Imfinzi fails in late-stage trial to treat certain lung cancers
26 Jun 2024 //
REUTERS
IMFINZI shows results in Phase III trial for muscle-invasive bladder cancer.
25 Jun 2024 //
BUSINESSWIRE
AZ Imfinzi plus chemotherapy gets US nod for certain type of endometrial cancer
17 Jun 2024 //
REUTERS
Astrazeneca Uk Biologic Durvalumab Receives Suppl Approval in US
14 Jun 2024 //
FDA
IMFINZI Reduces Death Risk By 27% In Limited-Stage SCLC
02 Jun 2024 //
BUSINESSWIRE
As Bristol Myers reveals trial failure, AstraZeneca`s Imfinzi stays king in stage 3 lung cancer
14 May 2024 //
FIERCE PHARMA
AIM ImmunoTech: Ampligen+Imfinzi Combo Tolerated in Pancreatic Cancer Study
29 Apr 2024 //
GLOBENEWSWIRE
AstraZeneca’s earnings surprise investors as cancer drugs fuel growth
26 Apr 2024 //
BIOPHARMADIVE
AstraZeneca UK Imfinzi (Durvalumab) Receives Approval in the U.S.
22 Apr 2024 //
FDA
IMFINZI® + Chemo Doubled 3-Yr OS In Biliary Tract Cancer TOPAZ-1
16 Apr 2024 //
BUSINESSWIRE
AstraZeneca`s Imfinzi improves survival in late-stage lung cancer trial
06 Apr 2024 //
REUTERS
IMFINZI Significantly Improved Overall Survival in ADRIATIC Phase III Trial
05 Apr 2024 //
BUSINESSWIRE
AstraZeneca Shows Lynparza Combo Could Address Unmet Endometrial Cancer Need
19 Mar 2024 //
BIOSPACE
AIM ImmunoTech Announces First Subject Dosed for Phase 1b/2 Evaluating Ampligen
14 Feb 2024 //
GLOBENEWSWIRE
AIM ImmunoTech Announces Enrollment in the Phase 1b/2 Evaluating Ampligen
22 Jan 2024 //
GLOBENEWSWIRE
AstraZeneca`s Imfinzi combo extends PFS in liver cancer
19 Jan 2024 //
ENDPTS
AIM ImmunoTech Announces Open Enrollment for Ph 1b/2 Study Evaluating Ampligen
10 Jan 2024 //
GLOBENEWSWIRE
AstraZeneca`s Biologic Imfinzi (durvalumab) Receives Approval in the U.S.
20 Dec 2023 //
FDA
BioCity announces first patient dosed with anti-TIM-3 mAb BC3402 with IMFINZI
20 Dec 2023 //
PR NEWSWIRE
Imfinzi plus chemotherapy approved in China as first immunotherapy regimen
14 Nov 2023 //
PRESS RELEASE
AstraZeneca`s Imfinzi plus chemoradiotherapy fail main goal of late stage trial
14 Nov 2023 //
REUTERS
IMFINZI & bevacizumab met endpoint for progression-free survival in liver cancer
09 Nov 2023 //
BUSINESSWIRE
Theriva Presents Survival Outcomes Data from Phase 1 Study Evaluating VCN-01
23 Oct 2023 //
GLOBENEWSWIRE
Datopotamab deruxtecan plus IMFINZI Shows Durable tumor responses in BEGONIA Ph Ib/II trial
22 Oct 2023 //
BUSINESSWIRE
IMFINZI plus LYNPARZA reduced the risk of death by 45% in endometrial cancer
21 Oct 2023 //
BUSINESSWIRE
IMFINZI plus chemotherapy doubled pathologic complete response rate in GEJ
20 Oct 2023 //
BUSINESSWIRE
Datopotamab Deruxtecan Plus Durvalumab Showed Promising Activity in the NSCLC
10 Sep 2023 //
BUSINESSWIRE
Perioperative Durvalumab Plus SOC Shows Promising EFS Results Muscle-Invasive UC
31 Aug 2023 //
ONCLIVE
IMFINZI plus IMJUDO® demonstrated sustained overall survival benefit in ALC
29 Jun 2023 //
BUSINESSWIRE
First Patient Dosed in Ph2 MATISSE Trial of IPH5201 in Early Stage Lung Cancer
26 Jun 2023 //
BUSINESSWIRE
LYNPARZA & IMFINZI combination reduced risk of death in advanced ovarian cancer
03 Jun 2023 //
BUSINESSWIRE
IMFINZI plus chemotherapy improved response in MATTERHORN PIII trial
02 Jun 2023 //
BUSINESSWIRE
AstraZeneca reports positive results from endometrial cancer therapy trial
30 May 2023 //
CLINICAL TRIALS ARENA
Imfinzi plus Lynparza and Imfinzi alone both improved progression-free survival in advanced endometrial cancer
26 May 2023 //
PRESS RELEASE
Imfinzi plus Lynparza and Imfinzi alone both significantly improved progression
26 May 2023 //
ENDPTS
BMS accuses AZ of Opdivo patent infringement in new lawsuit
03 May 2023 //
FIERCE PHARMA
AZ`s Imfinzi-Lynparza will face tough FDA scrutiny: analyst
06 Apr 2023 //
FIERCE PHARMA
IMFINZI significantly improved event-free survival in AEGEAN Phase III trial
09 Mar 2023 //
BUSINESSWIRE
AZ says cancer drug Imfinzi improves survival chances in late-stage trial
09 Mar 2023 //
NASDAQ
Imfinzi plus Imjudo approved in the EU for patients with NSCLC
23 Feb 2023 //
PRESS RELEASE
AstraZeneca gets CDSCO nod for drug to treat biliary tract cancer
17 Feb 2023 //
ECONOMIC TIMES
Merck`s Keytruda takes another hit in prostate cancer
26 Jan 2023 //
FIERCE PHARMA
BMS claims AstraZeneca`s Imjudo violates two Yervoy patents
25 Jan 2023 //
FIERCE PHARMA
Japan’s MHLW approves AstraZeneca’s Imfinzi, Imjudo for liver, lung cancers
29 Dec 2022 //
PHARMACEUTICAL-TECHNOLOGY
Imfinzi plus chemotherapy approved in the EU as first immunotherapy regimen
21 Dec 2022 //
PRESS RELEASE
